Snell V, Clodi K, Zhao S, Goodwin R, Thomas E K, Morris S W, Kadin M E, Cabanillas F, Andreeff M, Younes A
Department of Hematology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Br J Haematol. 1997 Dec;99(3):618-24. doi: 10.1046/j.1365-2141.1997.4393250.x.
T-cell cytotoxicity is primarily mediated by two cell surface proteins, Fas ligand (FasL) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), and intracellular perforin and granzyme granules. FasL-deficient and perforin-deficient T lymphocytes maintain cytotoxicity but fail to induce graft-versus-host disease (GVHD) when transplanted into mice. suggesting that GVHD and graft-versus-tumour (GVT) effects can be dissociated, and that TRAIL is not involved in the pathogenesis of GVHD. Because TRAIL could mediate a favourable GVT effect it became important to study the spectrum of its activity and to investigate factors that can dissociate its expression from FasL. TRAIL induced apoptosis in 11/41 (27%) tumour specimens of haematological origin compared to 16/41 (39%) induced by FasL. Although eight specimens were sensitive to both FasL and TRAIL, no synergism was observed between these two ligands. TRAIL induced apoptosis in a dose and time dependent manner with an ED50 of 0.5 microg/ml and EDmax of 1 microg/ml. TRAIL activity was not reduced by the over-expression of the multidrug resistant (MDR) protein, and was not enhanced by 9-cis retinoic acid (RA), which can down-regulate bcl-2 protein. Both ligands were simultaneously up-regulated in normal peripheral blood lymphocytes in response to IL-2, IL-15 and anti-CD3 antibody, whereas IL-10 had no effect. Together, our data show that (1) TRAIL can mediate cell death in a variety of human haematological malignancies, (2) resistance to TRAIL is not mediated by MDR protein, (3) the lack of synergy between TRAIL and FasL suggests that either one is sufficient to mediate T-cell cytotoxicity, and (4) within the panel of cytokines tested, the expression of TRAIL and FasL could not be dissociated.
T细胞的细胞毒性主要由两种细胞表面蛋白介导,即Fas配体(FasL)和肿瘤坏死因子相关凋亡诱导配体(TRAIL),以及细胞内的穿孔素和颗粒酶颗粒。FasL缺陷型和穿孔素缺陷型T淋巴细胞具有细胞毒性,但移植到小鼠体内时无法诱发移植物抗宿主病(GVHD)。这表明GVHD和移植物抗肿瘤(GVT)效应可以分离,且TRAIL不参与GVHD的发病机制。由于TRAIL可介导有益的GVT效应,因此研究其活性谱以及探究能使其表达与FasL分离的因素变得很重要。TRAIL可诱导11/41(27%)血液系统来源的肿瘤标本发生凋亡,而FasL可诱导16/41(39%)的肿瘤标本发生凋亡。尽管有8个标本对FasL和TRAIL均敏感,但未观察到这两种配体之间存在协同作用。TRAIL以剂量和时间依赖性方式诱导凋亡,半数有效剂量(ED50)为0.5微克/毫升,最大有效剂量(EDmax)为1微克/毫升。多药耐药(MDR)蛋白的过表达不会降低TRAIL的活性,9-顺式视黄酸(RA)可下调bcl-2蛋白,但也不会增强TRAIL的活性。在白细胞介素-2(IL-2)、白细胞介素-15(IL-15)和抗CD3抗体作用下,正常外周血淋巴细胞中这两种配体均同时上调,而IL-10则无此作用。总之,我们的数据表明:(1)TRAIL可介导多种人类血液系统恶性肿瘤细胞死亡;(2)对TRAIL的耐药性并非由MDR蛋白介导;(3)TRAIL和FasL之间缺乏协同作用表明二者任何一种都足以介导T细胞的细胞毒性;(4)在所测试的细胞因子中,TRAIL和FasL的表达无法分离。